Proton pump inhibitors for clopidogrel patients ‘not so dangerous’

By Piriya Mahendra

The interaction between proton pump inhibitors and clopidogrel is "clinically unimportant," say researchers in the BMJ.

Ian Douglas (London School of Hygiene and Tropical Medicine London, UK) and co-workers found that in a self-controlled case series analysis, to remove the effect of differences between people, there was no association between proton pump inhibitor use and myocardial infarction (MI) in patients prescribed clopidogrel and aspirin.

Moreover, there was no association with MI for other 2C19 inhibitors - fluoxetine and paroxetine - or non-2C19 inhibitors - citalopram and ranitidine - in these patients.

"The use of a proton pump inhibitor with clopidogrel and aspirin is well proved to prevent harm through gastrointestinal bleeding, and we should continue to consider proton pump inhibitors as important prophylactic drugs in patients at high risk," the authors write.

Of the 24,471 patients prescribed clopidogrel and aspirin who were included in the study, 12,439 (50%) were also prescribed a proton pump inhibitor at some point.

Death or MI occurred in 1419 (11%) patients while they received a proton pump inhibitor compared with 1341 (8%) patients who did not receive one.

Multivariate analysis showed that the hazard ratio for the association between proton pump inhibitor use and death or incident MI was 1.37.

Similar results were seen when the authors looked at the secondary outcomes of the study ‑ death, incident MI, vascular death, and nonvascular death - with exposure to drugs other than proton pump inhibitors that would not be expected to interact with clopidogrel.

Indeed, the results were comparable between other 2C19 inhibitors and non-2C19 inhibitors for these outcomes, at hazard ratios ranging from 1.13 to 1.73, and 1.14 to 1.84, respectively.

"These observed associations… suggest these results could be driven by important differences between proton pump inhibitor users and nonusers rather than showing a causal association," the authors remark.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation